Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remains an incurable disease. Novel immunotherapies, such as CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE), are intensively targeting different surface antigens, such as BMCA, SLAMF7 (CS1), GPRC5D, FCRH5 or CD38. However, stem cell transplantation is still indispensable in transplant-eligible patients. Studies suggest that the early use of immunotherapy may improve outcomes significantly. In this review, we summarize the currently available clinical literature on CAR and BiTE in MM. Furthermore, we will compare these two T cell-based immunotherapies and discuss potential therapeutic approaches to promote development of new clinical trials, using T cell-based immunotherapies, even as bridging therapies to a transplant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926 · cited 14×
“Thus, the CD4 + /CD8 + ratio is adjusted to 1:1 before CARs’ gene transfer in case of JCARH125 (NCT03430011) or after gene transfer in case of FCARH143 product (NCT03338972) [45].”
BackgroundInfluentialIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 2×
“6%) patients could not receive the CAR T product because of progressive disease, patient withdrawal, manufacturing issues or a decision of the treating physician [61].”
BackgroundSelf-citationTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 3×
“Other ways of generating CAR T cells include the use of non-viral methods such as CRISPR/Cas9 [12] or transposon systems [13, 14], or more recently, in vitro-transcribed mRNA was used to reprogram T cells in vivo [15].”
BackgroundBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationCAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800 · cited 1×
“Of note, the presence of extramedullary disease, high-risk cytogenetics or advanced disease (ISS = 3) was no longer associated with decreased response rates in the CARTITUDE-1 study; but disease progression was observed earlier (13 months for EMD or ISS3, 20 months for high-risk cytogenetics), and not reached for the…”
BackgroundB cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778 · cited 2×
“Cohen et al. showed no correlation between BCMA expression and response rate (NCT02546167) [46] as opposed to the FCARH143 trial (NCT03338972) [47].”
ResultPosey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.014 · Cited by 594
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391 · cited 1×
“In preclinical studies, anti-GPRC5D CARs generated no alopecia or any skin damage and were deemed safe and efficient [73].”
Backgroundγ-secretase directly sheds the survival receptor BCMA from plasma cells
Laurent, S. A., Hoffmann, F. S., Kuhn, P.-H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S. M., Schuh, E., Krumbholz, M., Rübsamen, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8333 · Cited by 377
Cited by
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Suehnholz, S. P., Nissan, M. H., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fernandez, N., Xu, B. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0467 · Cited by 401
Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., Wang, D., Luo, X., Cui, J., Huang, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00372-6 · Cited by 166
Theranostics in Hematooncology
Buck, A. K., Serfling, S. E., Kraus, S., Samnick, S., Dreher, N., Higuchi, T., Rasche, L., Einsele, H., & Werner, R. A. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265199 · Cited by 25
“Moreover, in recent years, novel and effective therapies have also entered the clinical arena, such as CAR T-cell therapies or bispecific T-cell engagers (34).”
BackgroundSelf-citationXia, J., Li, Z., & Xu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01461-1 · Cited by 13
A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
Li, H., Li, J., Wu, J., Shi, Z., Gao, Y., Song, W., Li, J., Li, Z., & Zhang, M. (2023) · Cancer Medicine · doi:10.1002/cam4.5818 · Cited by 7
Metadata
- Authors
- Kegyes, D., Constantinescu, C., Vrancken, L., Rasche, L., Gregoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J.
- Venue
- Journal of Hematology & Oncology
- Published
- 2022-06-07
- Volume
- 15
- Issue
- 1
- Pages
- 78-78
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W4281893236
- Cited by
- 62
- References
- 21
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? https://app.cochat.ai/papers/10.1186/s13045-022-01296-2
- The paper
- Kegyes, D., Constantinescu, C., Vrancken, L., Rasche, L., Gregoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J. (2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-022-01296-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.